1832 Asset Management L.P. Buys New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

1832 Asset Management L.P. bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 41,000 shares of the company’s stock, valued at approximately $5,402,000.

Other hedge funds have also recently added to or reduced their stakes in the company. FCF Advisors LLC acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $1,157,000. Norges Bank acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $35,731,000. abrdn plc raised its holdings in Neurocrine Biosciences by 2,503.0% during the fourth quarter. abrdn plc now owns 83,633 shares of the company’s stock worth $11,019,000 after purchasing an additional 80,420 shares in the last quarter. Redhawk Wealth Advisors Inc. acquired a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $1,245,000. Finally, HealthInvest Partners AB acquired a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $1,662,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other news, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Benevich sold 75,000 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the transaction, the insider now directly owns 40,778 shares of the company’s stock, valued at approximately $5,683,637.64. The disclosure for this sale can be found here. Insiders sold 208,997 shares of company stock valued at $28,773,215 in the last 90 days. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on NBIX. Oppenheimer raised their price objective on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. Citigroup raised their price objective on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Wedbush reissued an “outperform” rating and set a $152.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, May 29th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Monday, June 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $150.85.

View Our Latest Research Report on Neurocrine Biosciences

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $134.97 on Friday. Neurocrine Biosciences, Inc. has a one year low of $92.61 and a one year high of $148.37. The business has a fifty day moving average of $137.87 and a two-hundred day moving average of $133.61. The company has a market cap of $13.58 billion, a P/E ratio of 37.18 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). The firm had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Recommended Stories

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.